JP2001514493A - Zcytor7サイトカイン受容体 - Google Patents
Zcytor7サイトカイン受容体Info
- Publication number
- JP2001514493A JP2001514493A JP53678298A JP53678298A JP2001514493A JP 2001514493 A JP2001514493 A JP 2001514493A JP 53678298 A JP53678298 A JP 53678298A JP 53678298 A JP53678298 A JP 53678298A JP 2001514493 A JP2001514493 A JP 2001514493A
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- receptor
- seq
- zcytor7
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/14—Lymphokine; related peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.(a)配列番号2の残基30のバリンから残基250のリシンまで延びアミノ 酸残基の配列; (b)上記(a)の対立遺伝子変異体;及び (c)上記(a)又は(b)に対して少なくとも80%の同一性を有する配列; を含んで成る単離されたポリペプチド。 2.前記アミノ酸残基の配列が、残基30のバリンから残基274のチロシンまで 延びる請求の範囲第1項記載の単離されたポリペプチド。 3.前記アミノ酸残基の配列が、残基30のバリン残基から残基553のアスパラ ギン残基まで延びる請求の範囲第1項記載の単離されたポリペプチド。 4.少なくとも20個の長さのアミノ酸である、配列番号2の副配列を含むポリ ペプチド。 5.さらに、トランスメンブランドメイン、細胞内ドメイン又は両者を含んで 成る請求の範囲第1項記載のポリペプチド。 6.請求の範囲第1〜4のいづれか1項記載のポリペプチドをコードする単離 されたポリヌクレオチド。 7.請求の範囲第6項記載のポリヌクレオチド、及び次の作用可能に結合され た要素: 転写プロモーター; 請求の範囲第5項記載のポリヌクレオチド配列;及び転写ターミネーター; を含む発現ベクター。 8.抗体を生成するための方法であって、配列番号2により定義 されるポリペプチド、その副配列又は配列番号2の少なくとも20個のアミノ酸を 含むポリペプチドを動物に接種し、ここで前記動物が、配列番号2のポリペプチ ドに結合する抗体を生成し;そして 前記抗体を単離する、 ことを含んで成る方法。 9.請求の範囲第8項記載の方法により生成される抗体。 10.請求の範囲第9項記載の抗体に結合し、そしてそれを中和する抗−イディ オタイプ抗体。 11.請求の範囲第1〜4のいづれか1項記載のポリペプチドに特異的に結合す る抗体。 12.ペプチド結合により連結される第1部分及び第2部分から実質的に成るキ メラポリペプチドであって、前記第1部分が、 (a)残基30〜250を含む配列番号2に示されるような受容体ポリペプチド; (b)配列番号2の対立遺伝子変異体;及び (c)上に(a)又は(b)に対して少なくとも80%の同一性を有する受容体 ポリペプチド、 から成る群から選択された受容体ポリペプチドのリガンド結合ドメインから実 質的に成り;そして前記第2部分が親和性標識から実質的に成ることを特徴とす るキメラポリペプチド。 13.前記親和性標識が免疫グロブリンFcポリペプチドである請求の範囲第12項 記載のポリペプチド。 14.試験サンプル内のリガンドを検出するための方法であって、試験サンプル と、 (a)配列番号2の残基30〜250; (b)上記(a)の対立遺伝子変異体;及び (c)上記(a)又は(b)に対して少なくとも80%の同一性を 有する配列、 から成る群から選択されたセグメントを含んで成るポリペプチドとを接触せし め;そして 前記サンプル中のリガンドへの前記ポリペプチドの結合を検出することを含ん で成る方法。 15.前記ポリペプチドがさらに、トランスメンブラン及び細胞内ドメインを含 んで成る請求の範囲第14項記載の方法。 16.前記ポリペプチドが培養された細胞内に結合される膜であり、そして前記 検出段階が前記培養された細胞における生物学的応答を測定することを含んで成 る請求の範囲第15項記載の方法。 17.前記生物学的応答が、細胞増殖又はレポーター遺伝子の転写の活性化であ る請求の範囲第16項記載の方法。 18.前記ポリペプチドが固体支持体上に固定される請求の範囲第14項記載の方 法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80330597A | 1997-02-20 | 1997-02-20 | |
US08/803,305 | 1997-02-20 | ||
US08/943,087 US5945511A (en) | 1997-02-20 | 1997-10-02 | Class II cytokine receptor |
US08/943,087 | 1997-10-02 | ||
PCT/US1998/003029 WO1998037193A1 (en) | 1997-02-20 | 1998-02-18 | Zcytor7 cytokine receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2001514493A true JP2001514493A (ja) | 2001-09-11 |
Family
ID=27122570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53678298A Pending JP2001514493A (ja) | 1997-02-20 | 1998-02-18 | Zcytor7サイトカイン受容体 |
Country Status (6)
Country | Link |
---|---|
US (6) | US5945511A (ja) |
EP (2) | EP1616884A3 (ja) |
JP (1) | JP2001514493A (ja) |
AU (1) | AU6535098A (ja) |
CA (1) | CA2281491C (ja) |
WO (1) | WO1998037193A1 (ja) |
Families Citing this family (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5945511A (en) * | 1997-02-20 | 1999-08-31 | Zymogenetics, Inc. | Class II cytokine receptor |
US5965704A (en) * | 1997-08-05 | 1999-10-12 | Zymogenetics, Inc. | Class two cytokine receptor-11 |
US6927044B2 (en) * | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
US20030199041A1 (en) | 1999-07-07 | 2003-10-23 | Presnell Scott R. | Interleukin-17 receptor homologue |
DE60045931D1 (de) * | 1999-07-07 | 2011-06-16 | Zymogenetics Inc | Menschliches Rezeptor für Zytokine |
US6346247B1 (en) | 1999-10-28 | 2002-02-12 | Promega Corporation | Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
EP1230368A2 (en) * | 1999-11-18 | 2002-08-14 | Schering Corporation | Mammalian receptor proteins; related reagents and methods |
CA2393369A1 (en) | 1999-12-03 | 2001-06-07 | Zymogenetics, Inc. | Human cytokine receptor |
EP2295079A3 (en) * | 1999-12-23 | 2011-03-23 | ZymoGenetics, L.L.C. | Method for treating inflammation |
CA2395539C (en) | 1999-12-23 | 2009-08-25 | Zymogenetics, Inc. | Soluble interleukin-20 receptor |
US20030170823A1 (en) | 1999-12-23 | 2003-09-11 | Presnell Scott R. | Novel cytokine ZCYTO18 |
US7122632B2 (en) | 1999-12-23 | 2006-10-17 | Zymogenetics, Inc. | Soluble Interleukin-20 receptor |
US6610286B2 (en) * | 1999-12-23 | 2003-08-26 | Zymogenetics, Inc. | Method for treating inflammation using soluble receptors to interleukin-20 |
CN1320611A (zh) * | 2000-04-27 | 2001-11-07 | 上海博德基因开发有限公司 | 一种新的多肽——细胞因子受体15和编码这种多肽的多核苷酸 |
CN1331177A (zh) * | 2000-06-28 | 2002-01-16 | 上海博德基因开发有限公司 | 一种新的多肽——人细胞因子受体13.31和编码这种多肽的多核苷酸 |
DK1717316T3 (da) | 2000-06-30 | 2008-12-08 | Zymogenetics Inc | Allelisk variant af interferon-lignende protein Zcyto21 |
EP2177616B1 (en) * | 2000-08-08 | 2012-02-29 | ZymoGenetics, Inc. | Soluble zcytor 11 cytokine receptors |
EP1351703B1 (en) * | 2000-09-15 | 2006-07-26 | ZymoGenetics, Inc. | Use of a polypeptide comprising the extracellular domains of il-20ra and il-20rb for the treatment of inflammation |
PT1356046E (pt) | 2000-11-28 | 2010-03-09 | Zymogenetics L L C | Receptor de citocina zcytor19 |
US20040019193A1 (en) * | 2001-01-26 | 2004-01-29 | Peng Liang | Mob-5/hmob-5 as a cancer diagnostic marker |
EP1370676A4 (en) | 2001-03-02 | 2004-09-22 | Zymogenetics Inc | CYTOKIN RECEPTOR FROM MOUSE |
EP1373508B1 (en) * | 2001-03-27 | 2013-04-24 | ZymoGenetics, Inc. | Human cytokine receptor |
ATE482272T1 (de) | 2001-04-20 | 2010-10-15 | Zymogenetics L L C | Zytokinproteinfamilie |
DK2000545T3 (da) * | 2001-06-20 | 2011-11-28 | Genentech Inc | Sammensætninger og fremgangsmåder til diagnose og behandling af lunge-tumor |
US20050272120A1 (en) | 2001-06-20 | 2005-12-08 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US20030108958A1 (en) * | 2001-06-28 | 2003-06-12 | Rene De Waal Malefyt | Biological activity of AK155 |
US6902930B2 (en) * | 2001-08-29 | 2005-06-07 | Vanderbilt University | Human Mob-5 (IL-24) receptors and uses thereof |
US20040204351A1 (en) * | 2001-10-22 | 2004-10-14 | Rowlinson Scott William | Soluble proteins that inhibit cytokine signal transduction pathways |
TW200300170A (en) * | 2001-11-09 | 2003-05-16 | Wyeth Corp | Type 2 cytokine receptor and nucleic acids encoding same |
US20030018172A1 (en) * | 2001-12-06 | 2003-01-23 | Genentech, Inc. | Secreted transmembrane polypeptides and nucleic acids encoding the same |
US7582287B2 (en) * | 2001-12-17 | 2009-09-01 | Zymogenetics, Inc. | Method for treating cervical cancer |
US7265211B2 (en) | 2002-03-22 | 2007-09-04 | Zymogenetics, Inc. | Anti-IL-TIF antibodies and methods of making |
EP1497415B1 (en) | 2002-04-19 | 2010-12-29 | ZymoGenetics, L.L.C. | Methods for detection or modulation of the interaction of a cytokine receptor with its ligand |
ES2347657T3 (es) * | 2003-03-24 | 2010-11-03 | Zymogenetics, Inc. | Anticuerpos dirigidos contra il-22ra y asociados de union y procedimiento de uso en inflamacion. |
EP2251352A1 (en) | 2003-08-07 | 2010-11-17 | ZymoGenetics, L.L.C. | Homogeneous preparations of IL-28 and IL-29 |
DK1725249T3 (en) | 2003-11-06 | 2014-03-17 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugating to ligands. |
JP2007537993A (ja) * | 2003-11-21 | 2007-12-27 | ザイモジェネティクス, インコーポレイテッド | 抗il−20受容体抗体および結合パートナーならびに炎症において用いる方法 |
US20050132599A1 (en) * | 2003-12-18 | 2005-06-23 | Lg Electronics Inc. | Drying method of washing machine and apparatus thereof |
CA2558811A1 (en) | 2004-03-08 | 2005-09-22 | Zymogenetics, Inc. | Dimeric fusion proteins and materials and methods for producing them |
BRPI0510883B8 (pt) | 2004-06-01 | 2021-05-25 | Genentech Inc | composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação |
AU2005254998B2 (en) | 2004-06-10 | 2011-10-27 | Zymogenetics, Inc. | Soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners and methods of using in inflammation |
CA2574564C (en) | 2004-07-29 | 2013-04-16 | Zymogenetics, Inc. | Use of il-28 and il-29 to treat cancer and autoimmune disorders |
US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
DE602005022475D1 (de) * | 2004-10-22 | 2010-09-02 | Zymogenetics Inc | Anti-il-22ra-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen |
CA2596390A1 (en) | 2005-02-08 | 2006-08-17 | Zymogenetics, Inc. | Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation |
US20070249533A1 (en) | 2005-09-28 | 2007-10-25 | Levin Steven D | Il-17a and il-17f antagonists and methods of using the same |
ES2347840T3 (es) | 2006-02-10 | 2010-11-04 | Zymogenetics, Inc. | Il-17rcx4 soluble y procedimiento de utilizacion en la inflamacion. |
US7790676B2 (en) | 2007-03-28 | 2010-09-07 | Zymogenetics, Inc. | Soluble IL-17RA/RC fusion proteins |
IN2012DN03025A (ja) | 2009-09-09 | 2015-07-31 | Ct Se Llc | |
SI3409289T1 (sl) | 2010-02-26 | 2020-12-31 | Novo Nordisk A/S | Stabilni sestavki, ki vsebujejo protitelo |
US20130028917A1 (en) | 2010-04-15 | 2013-01-31 | Spirogen Developments Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
CN102905692B (zh) | 2010-05-28 | 2015-09-16 | 诺沃—诺迪斯克有限公司 | 包含抗体和防腐剂的稳定的多剂量组合物 |
WO2011156328A1 (en) | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
EP2640727B1 (en) | 2010-11-17 | 2015-05-13 | Genentech, Inc. | Alaninyl maytansinol antibody conjugates |
JP5987053B2 (ja) | 2011-05-12 | 2016-09-06 | ジェネンテック, インコーポレイテッド | フレームワークシグネチャーペプチドを用いて動物サンプルにおける治療抗体を検出するための多重反応モニタリングlc−ms/ms法 |
AU2012322607B2 (en) | 2011-10-14 | 2017-02-16 | Genentech, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
ME03486B (me) | 2012-10-12 | 2020-01-20 | Medimmune Ltd | Pirolobenzodiazepini i njihovi konjugati |
EP2906297B1 (en) | 2012-10-12 | 2017-12-06 | ADC Therapeutics SA | Pyrrolobenzodiazepine-antibody conjugates |
CA2887899C (en) | 2012-10-12 | 2020-03-31 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
EP2906298B1 (en) | 2012-10-12 | 2018-10-03 | ADC Therapeutics SA | Pyrrolobenzodiazepine-antibody conjugates |
LT2906253T (lt) | 2012-10-12 | 2018-10-10 | Adc Therapeutics Sa | Pirolobenzodiazepino-anti-psma antikūno konjugatas |
PT2906296T (pt) | 2012-10-12 | 2018-06-01 | Medimmune Ltd | Conjugados de pirrolobenzodiazepina-anticorpo |
ES2680153T3 (es) | 2012-10-12 | 2018-09-04 | Adc Therapeutics Sa | Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas |
EA031585B1 (ru) | 2012-12-21 | 2019-01-31 | Медимьюн Лимитед | Пирролобензодиазепины и их конъюгаты |
US9567340B2 (en) | 2012-12-21 | 2017-02-14 | Medimmune Limited | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
CN105209077B (zh) | 2013-03-13 | 2019-06-11 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓以及其结合物 |
CA2904044C (en) | 2013-03-13 | 2020-03-31 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
AR096287A1 (es) | 2013-03-13 | 2015-12-23 | Spirogen Sàrl | Pirrolobenzodiacepinas y conjugados |
US10442836B2 (en) | 2013-08-12 | 2019-10-15 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1H-benzo[E]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
WO2015052534A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
WO2015052532A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
EP3054986B1 (en) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
MX2016007578A (es) | 2013-12-16 | 2016-10-03 | Genentech Inc | Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo [e] indol, y metodos de uso y tratamiento. |
MX2016007826A (es) | 2013-12-16 | 2017-03-31 | Genentech Inc | Compuestos peptidomimeticos y sus conjugados de anticuerpo-farmaco. |
BR112016012410A2 (pt) | 2013-12-16 | 2017-09-26 | Genentech Inc | conjugado de droga e anticorpo, composto conjugado de droga e anticorpo, composto não-peptídico, método de tratamento de doenças em seres humanos e composição farmacêutica |
US10188746B2 (en) | 2014-09-10 | 2019-01-29 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
WO2016040825A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
CN107108724A (zh) | 2014-09-12 | 2017-08-29 | 豪夫迈·罗氏有限公司 | 半胱氨酸改造抗体和缀合物 |
SG11201702079UA (en) | 2014-09-17 | 2017-04-27 | Genentech Inc | Pyrrolobenzodiazepines and antibody disulfide conjugates thereof |
CA2968447A1 (en) | 2014-11-25 | 2016-06-02 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates and their use to treat neoplasms |
CA2969689A1 (en) | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Quaternary amine compounds and antibody-drug conjugates thereof |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
MA45326A (fr) | 2015-10-20 | 2018-08-29 | Genentech Inc | Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation |
GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
EP3433621A1 (en) | 2016-03-25 | 2019-01-30 | H. Hoffnabb-La Roche Ag | Multiplexed total antibody and antibody-conjugated drug quantification assay |
GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
ES2858151T3 (es) | 2016-05-20 | 2021-09-29 | Hoffmann La Roche | Conjugados de PROTAC-anticuerpo y procedimientos de uso |
CN109313200B (zh) | 2016-05-27 | 2022-10-04 | 豪夫迈·罗氏有限公司 | 用于表征位点特异性抗体-药物缀合物的生物分析性方法 |
EP3464280B1 (en) | 2016-06-06 | 2021-10-06 | F. Hoffmann-La Roche AG | Silvestrol antibody-drug conjugates and methods of use |
JP7093767B2 (ja) | 2016-08-11 | 2022-06-30 | ジェネンテック, インコーポレイテッド | ピロロベンゾジアゼピンプロドラッグ及びその抗体コンジュゲート |
JP7050770B2 (ja) | 2016-10-05 | 2022-04-08 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 抗体薬物コンジュゲートの調製方法 |
GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
KR20200032243A (ko) | 2017-02-08 | 2020-03-25 | 에이디씨 테라퓨틱스 에스에이 | 피롤로벤조디아제핀-항체 컨주게이트 |
PT3612537T (pt) | 2017-04-18 | 2022-08-29 | Medimmune Ltd | Conjugados de pirrolobenzodiazepina |
EP3612234B1 (en) | 2017-04-20 | 2024-03-13 | ADC Therapeutics SA | Combination therapy with an anti-axl antibody-drug conjugate |
UA127900C2 (uk) | 2017-06-14 | 2024-02-07 | Ейдісі Терапьютікс Са | Схема дозування для введення adc до cd19 |
DK3668874T3 (da) | 2017-08-18 | 2022-02-14 | Medimmune Ltd | Pyrrolobenzodiazepin-konjugater |
RU2020113749A (ru) | 2017-09-20 | 2021-10-20 | пиЭйч ФАРМА Ко., ЛТД. | Аналоги таиланстатина |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
TW202037381A (zh) | 2018-10-24 | 2020-10-16 | 瑞士商赫孚孟拉羅股份公司 | 綴合化學降解誘導劑及使用方法 |
WO2020123275A1 (en) | 2018-12-10 | 2020-06-18 | Genentech, Inc. | Photocrosslinking peptides for site specific conjugation to fc-containing proteins |
GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0638644A1 (en) * | 1993-07-19 | 1995-02-15 | F. Hoffmann-La Roche Ag | Receptors of interleukin-12 and antibodies |
FR2733250B1 (fr) * | 1995-04-21 | 1997-07-04 | Diaclone | Anticorps monoclonaux anti-gp130, et leurs utilisations |
US5945511A (en) * | 1997-02-20 | 1999-08-31 | Zymogenetics, Inc. | Class II cytokine receptor |
EP1719780A3 (en) * | 1997-11-26 | 2006-12-20 | ZymoGenetics, Inc. | Mammalian cytokine-like polypeptide-10 |
JP2007537993A (ja) * | 2003-11-21 | 2007-12-27 | ザイモジェネティクス, インコーポレイテッド | 抗il−20受容体抗体および結合パートナーならびに炎症において用いる方法 |
-
1997
- 1997-10-02 US US08/943,087 patent/US5945511A/en not_active Expired - Lifetime
-
1998
- 1998-02-18 JP JP53678298A patent/JP2001514493A/ja active Pending
- 1998-02-18 EP EP05019282A patent/EP1616884A3/en not_active Withdrawn
- 1998-02-18 CA CA002281491A patent/CA2281491C/en not_active Expired - Fee Related
- 1998-02-18 AU AU65350/98A patent/AU6535098A/en not_active Abandoned
- 1998-02-18 WO PCT/US1998/003029 patent/WO1998037193A1/en not_active Application Discontinuation
- 1998-02-18 EP EP98911383A patent/EP1009825A1/en not_active Withdrawn
-
2001
- 2001-05-21 US US09/861,779 patent/US6686448B2/en not_active Expired - Lifetime
-
2003
- 2003-08-07 US US10/636,716 patent/US20060160091A9/en not_active Abandoned
-
2008
- 2008-06-09 US US12/135,677 patent/US20090074799A1/en not_active Abandoned
-
2009
- 2009-10-01 US US12/571,563 patent/US20100099184A1/en not_active Abandoned
-
2010
- 2010-10-07 US US12/899,819 patent/US20110054158A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20050244832A9 (en) | 2005-11-03 |
US20110054158A1 (en) | 2011-03-03 |
EP1009825A1 (en) | 2000-06-21 |
US20040072229A1 (en) | 2004-04-15 |
US6686448B2 (en) | 2004-02-03 |
WO1998037193A1 (en) | 1998-08-27 |
CA2281491C (en) | 2009-09-01 |
US20060160091A9 (en) | 2006-07-20 |
EP1616884A2 (en) | 2006-01-18 |
US20100099184A1 (en) | 2010-04-22 |
CA2281491A1 (en) | 1998-08-27 |
US20090074799A1 (en) | 2009-03-19 |
US20030191280A1 (en) | 2003-10-09 |
US5945511A (en) | 1999-08-31 |
AU6535098A (en) | 1998-09-09 |
EP1616884A3 (en) | 2007-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001514493A (ja) | Zcytor7サイトカイン受容体 | |
US5965704A (en) | Class two cytokine receptor-11 | |
EP0910635B1 (en) | Hematopoietic cytokine receptor | |
FI116943B (fi) | Menetelmä kasvainkuoliotekijän reseptoria sisältävien fuusioproteiinien valmistamiseksi ja niitä koodaava DNA ja vektori | |
US20020187472A1 (en) | Steap-related protein | |
US20020106655A1 (en) | Human GPCR proteins | |
JP4208960B2 (ja) | オピオイドレセプター遺伝子 | |
US20160282350A1 (en) | Methods of diagnosing cancer | |
WO1998049307A1 (en) | Mammalian cytokine-like receptor | |
US6590089B1 (en) | RVP-1 variant differentially expressed in Crohn's disease | |
US6632617B1 (en) | Tumor-associated antigen | |
JP2001525195A (ja) | 哺乳類アルファ螺旋蛋白質−1 | |
US6271343B1 (en) | Mammalian cytokine-like receptor 5 | |
US6303770B1 (en) | Nucleic acids encoding mammalian alpha helical protein-1 | |
US20020025555A1 (en) | GPCR diagnostic for brain cancer | |
US20030100046A1 (en) | Testis-specific receptor | |
JP2002533109A (ja) | ヒトBrainiac−5 | |
CA2422508A1 (en) | Atp-binding cassette protein | |
US20020146767A1 (en) | Human EMR1-like G protein-coupled receptor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041215 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20050323 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20050323 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070424 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090127 |